Clinical trials: Withdrawal Syndrome
Alcohol Withdrawal, Lactic Acidosis
Alcohol: Thiamine and or Magnesium 1
Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency causing Wernicke's Encephalopathy (WE).
- Conditions
- Alcohol Withdrawal, Lactic Acidosis, Vitamin B1 Deficiency, Magnesium Deficiency
- Trial name
- AToM1 (NCT03466528)
- Testing
- Magnesium Sulfate, Pabrinex
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Glasgow Royal Infirmary
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Alcohol Withdrawal Syndrome, Alcohol Dependence
Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results.
- Trial name
- GATE I (NCT02090504)
- Testing
- Sodium Oxybate (SMO), Oxazepam
- Where
- 3 sites in Austria, Italy
- Volunteers
- 127 people
- Sponsor
- Catholic University of the Sacred Heart
Opioid-Related Disorders, Drug Addiction
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1).
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse
- Trial name
- MOMs-INO (NCT03911739)
- Testing
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Where
- 10 sites in United States
- Volunteers
- 71 people
- Sponsor
- T. John Winhusen, PhD
Topiramate, Lamotrigine
Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome
The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome
- Conditions
- Topiramate, Lamotrigine, Memnatine, Diazepam
- Trial name
- NCT00241995
- Testing
- Anticonvulsants
- Volunteers
- healthy volunteers welcome
- Sponsor
- St. Petersburg State Pavlov Medical University
Alcohol Withdrawal Delirium
Treating Alcohol Withdrawal With Oral Baclofen
The purpose of this study is determine if subjects with alcohol withdrawal who receive oral baclofen, plus standard benzodiazepine therapy, will experience less severe withdrawal symptoms than those who receive placebo plus…
- Trial name
- NCT00597701
- Testing
- Baclofen, Lorazepam
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Essentia Health
Invasive Ventilation, Infant Pain
Dexmedetomidine for Invasive Ventilation In the NEOnate
Despite the increasing use of non-invasive ventilation, a large majority of premature neonates still receive invasive ventilation during their NICU (neonatal intensive care unit) stay.
- Conditions
- Invasive Ventilation, Infant Pain, Infant Discomfort, Infant Neurodevelopment
- Trial name
- NCT07493785
- Testing
- Dexmedetomidine Injectable Solution, Glucose 5% Injectable Solution
- Where
- 12 sites in France
- Volunteers
- 246 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Opioid-use Disorder, Opioid Withdrawal
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
Clinical performance data for transcutaneous auricular neurostimulation (tAN) as a method to aid in the reduction of symptoms associated with opioid withdrawal in order to support clinical substantial equivalence to a predicate…
- Trial name
- NCT04075214
- Testing
- transcutaneous auricular neurostimulation (tAN)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Spark Biomedical, Inc.
Substance Withdrawal Syndrome
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain…
- Trial name
- NCT02643355
- Testing
- Olanzapine, Clonidine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hennepin Healthcare Research Institute
Neonatal Opioid Withdrawal Syndrome
Use of SVS Device to Improve Outcomes for Neonatal Opioid Withdrawal Syndrome.
Maternal use and addiction to opioids has resulted in an unprecedented rise in drug withdrawal complications in newborns known as neonatal opioid withdrawal syndrome (NOWS), also referred to as neonatal abstinence syndrome (NAS).
- Trial name
- NCT04834297
- Testing
- Prapela SVS mattress
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Tufts Medical Center
Irritable Bowel Syndrome
Multicenter Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment
This study is a withdrawal randomized clinical trail to evaluate the clinical efficacy and safety of 1.1 chemical drugs N-acetyl glucosamine on Chinese IBS-D patients coming from four centers in chongqing.
- Trial name
- NCT01893606
- Testing
- N-acetyl-D-glucosamine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Phelan McDermid Syndrome
Growth Hormone Treatment in Children With Phelan McDermid Syndrome
Phelan McDermid syndrome (PMS) is a rare genetic form of autism spectrum disorder (ASD) due to deletions or mutations in the SHANK3 gene.
- Trial name
- NCT04003207
- Testing
- Recombinant human Growth hormone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Swathi Sethuram
HIV Infections
A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)
To determine if methadone treatment will affect the blood levels of zidovudine (AZT) in patients with AIDS or AIDS-related complex (ARC) who are receiving oral AZT and methadone therapy.
- Trial name
- NCT00001008
- Testing
- Methadone hydrochloride, Zidovudine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sleep Apnea, Obstructive
Effects of Suboptimal CPAP Therapy on Symptoms of Obstructive Sleep Apnoea
Obstructive sleep apnoea (OSA) is a highly prevalent sleep-related breathing disorder. The most effective treatment for OSA is continuous positive airway pressure (CPAP).
- Trial name
- NCT02781740
- Testing
- Continous Positive Air Pressure Device
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University of Zurich
E-cigarette Use, Withdrawal
Evaluation of the Electronic Cigarette Withdrawal Syndrome
The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.
- Trial name
- NCT06066996
- Testing
- Transdermal Nicotine Patch
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Addiction, Substance, Alcohol Use Disorder
Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)
The goal of this observational study is to validate the French version of the PAWSS scale in a population of patients with Alcohol Use Disorders.
- Conditions
- Addiction, Substance, Alcohol Use Disorder, Alcohol Dependence, Alcohol Withdrawal
- Trial name
- PAWSS-VF (NCT06675539)
- Testing
- French version PAWSS
- Where
- France
- Volunteers
- 545 people
- Sponsor
- Etablissement Public de Santé Barthélemy Durand
Neonatal Opioid Withdrawal Syndrome
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome
- Trial name
- NOWSHINE (NCT04104646)
- Testing
- CHF6563, Morphine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Alcohol Withdrawal Symptoms, Delirium Tremens (DTs)
Hyperbaric Oxygenation in Treatment of Alcohol Dependence Syndrome
A 30 alcohol dependent patients were divided into A: Treatment group and B: Placebo group using simple randomization technique. (Liver function tests) GGT, ALT and AST levels and MCV (Mean corpuscular volume) at admission and 2…
- Trial name
- NCT03470168
- Testing
- Hyperbaric Oxygenation Therapy, Normobaric Oxygenation therapy
- Volunteers
- 30 people
- Sponsor
- Jubilee Mission Medical College and Research Institute
Drug Withdrawal Symptoms, Critical Care
Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment
The study is a prospective interventional study with three main aims: 1. Describe the frequency and severity of withdrawal syndrome in a population of paediatric intensive care patients. 2.
- Conditions
- Drug Withdrawal Symptoms, Critical Care, Child
- Trial name
- ASWISPIC (NCT02952846)
- Testing
- Algorithm for tapering og analgosedation
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Oslo University Hospital